Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10398762

    Methods and compositions for treating diabetes

    Oramed Ltd. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10398769

    Influenza nucleic acid molecules and vaccines made therefrom

    Inovio Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10399189

    Airfoil aerodynamics

    UNITED TECHNOLOGIES CORPORATION · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10398776

    Phonophoretic cannabidiol composition and transdermal delivery system

    Essential Green Goodness LLC · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10399937

    Ionizable cationic lipid for RNA delivery

    ARCTURUS THERAPEUTICS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10398778

    Method for enhancing specific immunotherapies in cancer treatment

    Providence Health & Services—Oregon · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10399943

    Antifungal compound process

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10399962

    Azolopyrimidine for the treatment of cancer-related disorders

    Arcus Biosciences, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10400006

    Estrogen receptor modulators

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10400010

    Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeutics

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10399993

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Lixte Biotechnology, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10400036

    Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin A

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10400225

    TAL effector-mediated DNA modification

    Regents of the University of Minnesota · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10400029

    Serpin fusion polypeptides and methods of use thereof

    Inhibrx, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10400025

    VEGF antagonist formulations suitable for intravitreal administration

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10400031

    Identification of antibodies specific for lyssaviruses and methods of their use

    The Government of the United States of America as represented by the Secretary of the Deptartment of Health and Human Services · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10400045

    Internalizing human monoclonal antibodies targeting prostate and other cancer cells

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10400238

    Polynucleotide agents targeting complement component C5 and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10400239

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10400253

    Methods and compositions or RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. CA 3091946

    EXPANSION ET DIFFERENCIATION DE CELLULES SOUCHES

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Fri Sep 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Thu Sep 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10407392

    Antifungal compound process

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10406226

    Method of manufacturing VEGF antagonist fusion proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10407409

    6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10407443

    5-HT3 receptor antagonists

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10407466

    Methods of selecting compstatin mimetics

    Apellis Pharmaceuticals, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10407484

    Compositions and methods for modulating T-cell mediated immune response

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10408834

    Mutated parvovirus structural proteins as vaccines

    Ludwig-Maximilians-Universitat Munchen · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10407476

    Methods and compositions for treating hemophilia

    Sangamo Therapeutics, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10407445

    Hepatitis C virus inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10407468

    Methods for synthesizing α4β7 peptide antagonists

    Protagonist Therapeutics, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10407508

    Compositions and methods for increasing protein half-life in a serum

    Nanjing Legend Biotech Co., Ltd · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10406157

    Tetrahydropyridopyrazine modulators of GPR6

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10407414

    Mannose derivatives for treating bacterial infections

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10406146

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10407457

    Pyrrolopyrimidine nucleosides and analogs thereof

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10406160

    Sustained release small molecule drug formulation

    Indivior UK Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10407485

    Murine anti-NY-ESO-1 T cell receptors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10405560

    Method for making coffee products containing cannabis ingredients

    Blacklist Holdings, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10406167

    Texaphyrin-Pt(IV) conjugates and compositions for use in overcoming platinum resistance

    The Board of Regents of the University of Texas System · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10407403

    Preparation method of cobimetinib

    Suzhou Miracpharma Technology Co., Ltd. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10406214

    Propionyl-CoA carboxylase compositions and uses thereof

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10406177

    Modified cells and methods of therapy

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10407488

    Therapy for treatment or prevention of conditions associated with bleeding or hypocoagulation

    The Regents of the University of California · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10407405

    Nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10407416

    Kappa opioid agonists and uses thereof

    Nektar Therapeutics · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10407495

    Bispecific antibody fragments for neurological disease proteins and methods of use

    ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10407503

    Fully human antibodies and fragments recognizing human c-Met

    The Regents of the University of California · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.